Meta AnalysisID 6325
芪苈强心胶囊治疗缺血性心肌病的临床有效性与安全性：一项系统评价与Meta分析
CRD42022315279
In this study, the randomized controlled trial of Qili Qiangxin capsule combined with western medicine for ischemic cardiomyopathy will be organized, with systematic evaluation of efficacy and safety and Meta-analysis, s
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6325
- Evidence Id
- 14883
- Core Evidence Id
- 14883
- Source Meta Analysis Id
- 6309
- Herb2 Meta Analysis Id
- HBMA006309
- Crd Id
- CRD42022315279
- Title
- clinical efficacy and security of Qili Qiangxin Capsule for Ischemic cardiomyopathy: a systematic review and meta-analysis
- Review Question
- In this study, the randomized controlled trial of Qili Qiangxin capsule combined with western medicine for ischemic cardiomyopathy will be organized, with systematic evaluation of efficacy and safety and Meta-analysis, so as to provide evidence-based reference for clinical practice.
- Study Type Included
- Randomized controlled trials (RCTs) will be included.Animal studies were not considered.
- Condition Being Studied
- Ischemic cardiomyopathy is one of coronary atherosclerotic heart disease, because coronary atherosclerosis is more serious, myocardial in a state of ischemia for a long time, leading to myocardial relaxation and contraction function degeneration, heart expansion, stiffness phenomenon, heart failure is a serious complication of patients with ischemic cardiomyopathy, seriously affected the health level of patients.Studies have shown that Qiliqiangxin Capsule can regulate the neuroendocrine system, relieve cardiac cell damage, enhance heart function, reduce the heart load, so as to achieve the effect of treating heart failure.
- Participant
- Meet the Ischemic cardiomyopathy diagnostic criteria .
- Animal
- Human Disease Modelled
- Intervention
- The intervention was either Qiliqiangxin Capsule alone or Qiliqiangxin Capsule combined with conventional treatment.
- Comparator Control
- Conventional treatment or placebo.
- Main Outcome
- Clinical efficacy, LVEDD, LVESD, and LVEF Measures of effect As appropriate.
- Outcome Measure
- Additional Outcome
- 6MWT, BNP, NT-proBNP, and adverse reactions Measures of effect As appropriate.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Cardiomyopathies; Drugs, Chinese Herbal; Heart Failure; Humans; Treatment Outcome; qiangxin
- Contact
- Ruishi Wen [email protected]
- Organisational Affiliation
- Guangxi University of traditional Chinese Medicine
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Chinese-Simplified
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-03-07
- Registration Date
- 2022-04-07
- Anticipated Start Date
- 2022-03-07
- Anticipated Completion Date
- 2022-06-16
- Title Cn
- 芪苈强心胶囊治疗缺血性心肌病的临床有效性与安全性：一项系统评价与Meta分析
- Title En
- clinical efficacy and security of Qili Qiangxin Capsule for Ischemic cardiomyopathy: a systematic review and meta-analysis
- Bilingual Status
- complete